NeoGenomics said last week it finalized an agreement to acquire GE Healthcare‘s (NYSE:GE) cancer diagnostic subsidiary Clarient for up to $275 million. GE Healthcare originally purchased Clarient for nearly double that price at approximately $587 million in 2011. NeoGenomics said the acquisition would allow it to broaden its cancer diagnostic testing offerings to both hospitals and physicians […]
The Securities and Exchange Commission said today it charged a trio of individuals with insider training related to GE Healthcare‘s (NYSE:GE) purchase of cancer diagnostic company Clarient. The individuals include a father, son and personal friend accused of abusing confidential information the father learned from a close friend working at 1 of the companies, according to […]
General Electric Co.’s (NYSE:GE) healthcare unit closed its takeover of Clarient Inc. through a short-form merger in a $5-per-share cash deal worth about $587 million. GE’s buyout of the cancer diagnostic company is part of its strategy to grow is disease-diagnosis business, according to the company.